Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in vivo purging to enhance autografting in newly diagnosed multiple myeloma
2019-002147-20Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by University of Birmingham. Primary endpoint: MRD-negative bone marrow at day 100 post-ASCT. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-002147-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002147-20.